Purpose of the studyStudy of the natural course of MC in HIV-1 (+) treatmentnaïve patients at presentation, who will be followed-up regularly to delineate the time course of appearance and evolution or possible disappearance of MC in association with clinical and laboratory indices, therapy and clinical outcome (development of non-Hodgkin's lymphoma [NHL]).
MethodsCurrently diagnosed patients (n = 67, men = 58, women = 9, mean age = 39.17 years, Greeks = 55, foreigners = 12) at their first staging examination were tested for the presence of MC. All participating patients will be followed-up every 4 months.
Summary of resultsMC was found at presentation in four, in two in the first, second and third follow-up, and in the fourth and fifth follow-up, in one. Only in one patient, who was MC (+) in the first three tests, was CD8 lymphocytosis diagnosed. In the rest of the MC (+) patients, no evidence of NHL was found so far.
ConclusionMC has been found to occur in 27% of HIV-1 (+) patients (1996)(1997) [1], but its prevalence has declined during the HAART era (12/2003-07/2004) to 7.5% [2]. It is evident in the present study that MC is rare due possibly to earlier diagnosis and the use of HAART, but the long-term follow-up will clarify the phenomenon and give medical evidence as to whether the presence of MC is an indication for the initiation of treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.